VialOwlLibrary / Cognitive
P21
Also known as P021, Peptide 021
Animal studies only
Synthetic peptide derived from ciliary neurotrophic factor with an added adamantane group. Studied only in rodent models of ageing and Alzheimer disease.
Not an approved medicine. P21 is not an approved medicine for this use in Australia or the United States. This page summarises published research for information only. It is not a recommendation to use P21, and VialOwl does not sell or supply it.
Background
P21 (also P021) was designed by Khalid Iqbal's group at the New York State Institute for Basic Research in Developmental Disabilities and first reported in 2010. It is based on a short active region of ciliary neurotrophic factor (CNTF), with an adamantane group added to help it last longer and reach the brain.
How it is thought to work
It is thought to mimic the brain growth effects of CNTF, increasing brain derived neurotrophic factor (BDNF) and promoting the birth and maturation of new neurons in the hippocampus. In Alzheimer model mice it reduced tau and amyloid changes.
What is claimed, and the evidence
| Claim | Evidence | Notes |
|---|---|---|
| Improved learning and memory | Animal studies only | Shown in normal adult mice in the 2010 study. |
| Prevention or reversal of Alzheimer type changes | Animal studies only | Reduced amyloid and tau pathology and memory loss in 3xTg-AD mice; no human studies. |
| Cognitive enhancement, focus or mood in healthy people | No published evidence | Nootropic marketing and user claims; no human data. |
Side effects
| Effect | How often | Notes |
|---|---|---|
| Any human side effects | Frequency unknown | No published human studies of P21, so side effects in people are unknown. |
| Immune reactions or contamination Serious | Frequency unknown | General risk for unapproved injectable or nasal peptide products. |
Warnings
- No human safety or efficacy data have been published; all evidence is from rodents.
- Unapproved products are not assessed by the TGA for quality, safety or efficacy and may be contaminated, non-sterile, underdosed, overdosed or contain a different substance altogether.
Regulatory status
- Australia
- Not included on the ARTG (unapproved). Not specifically listed in the Poisons Standard (June 2026).
- United States
- Not FDA approved. No FDA compounding category entry found.
Sources
- PubMed: Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice
- PubMed: Prevention of amyloid-beta and tau pathologies by early treatment with a neurotrophic compound
Also in Cognitive
From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use P21.